ReviewBiological psychiatry1999
Epidemiology and natural history of schizophrenia.
Review in Biological psychiatry, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 142 citations in OpenAlex.
- Placebo effects in randomized trials of pharmacological and neurostimulation interventions for mental disorders: An umbrella review.Molecular psychiatry · 2024Pooled it
- The impact of informing psychiatric patients about their medication: a systematic review.Pharmacy world & science : PWS · 2006Pooled it
- Neurodegenerative model of schizophrenia: Growing evidence to support a revisit.Schizophrenia research · 2022Review
- Psychopharmacological Treatment of Schizophrenia Over Time in 30 908 Inpatients: Data From the AMSP Study.The international journal of neuropsychopharmacology · 2019Article
- Development of a nomogram for the estimation of long-term adherence to clozapine therapy using neutrophil fluorescence.British journal of clinical pharmacology · 2018Article
- Pharmacoinformatics, Adaptive Evolution, and Elucidation of Six Novel Compounds for Schizophrenia Treatment by Targeting DAOA (G72) Isoforms.BioMed research international · 2017Article
- TDO as a therapeutic target in brain diseases.Metabolic brain disease · 2016Review
- Schizophrenia and reelin: a model based on prenatal stress to study epigenetics, brain development and behavior.Biological research · 2016Review
- Implementing Coordinated Specialty Care for Early Psychosis: The RAISE Connection Program.Psychiatric services (Washington, D.C.) · 2015Article
- Adaptive evolution and elucidating the potential inhibitor against schizophrenia to target DAOA (G72) isoforms.Drug design, development and therapy · 2015Article
- Transcription factor 4 (TCF4) and schizophrenia: integrating the animal and the human perspective.Cellular and molecular life sciences : CMLS · 2014Review
- Similar and different gray matter deficits in schizophrenia patients and their unaffected biological relatives.Frontiers in psychiatry · 2013Review
- Drug treatment developments in schizophrenia and bipolar mania: latest evidence and clinical usefulness.Therapeutic advances in chronic disease · 2012Article
- Disease and genetic contributions toward local tissue volume disturbances in schizophrenia: a tensor-based morphometry study.Human brain mapping · 2012Article
- Targeting NOX enzymes in the central nervous system: therapeutic opportunities.Cellular and molecular life sciences : CMLS · 2012Review
- Is lead exposure in early life an environmental risk factor for Schizophrenia? Neurobiological connections and testable hypotheses.Neurotoxicology · 2012Review
- Article
- Diagnostic consistency of major depression with psychosis across 10 years.The Journal of clinical psychiatry · 2011Article
- Does olanzapine warrant clinical pharmacokinetic monitoring in schizophrenia?Clinical pharmacokinetics · 2011Review
- Changes in gene expression after phencyclidine administration in developing rats: a potential animal model for schizophrenia.International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience · 2011Article
Corrections and comments
- Commented on by
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
The present review explores the descriptive epidemiology of schizophrenia. Risk factors and correlates are divided into three groups based on whether the available evidence is consistent and strong, consistent and potentially strong, or inconsistent. The paper then considers epidemiologic studies of the course of illness, including a description of findings from the Suffolk County Mental Health Project. Given renewed attention to the need for preventive interventions for individuals at high risk for developing a psychotic illness, epidemiologic values have become more and more central to the conduct of clinical research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.